In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, members will receive ABBV-744 and ruxolitinib. Participants will receive treatment right up until sickness progression or even the individuals are not able to tolerate the study drugs. There may be increased treatment load for participants On this https://abbv-744preclinicalstudie58023.theobloggers.com/38111451/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know